Gene therapy for blood disorders
Fully diluted ownership
Value of Syncona holding
£31.0m (as at 31 August 2017)
Freeline Therapeutics is a biopharmaceutical company focused on the development of liver-directed gene therapies, based on the pioneering work of Professor Amit Nathwani at the University College London Royal Free Hospital.
The Company’s most advanced program is a treatment for haemophilia B, a rare disorder associated with deficiency in a blood clotting factor, that causes painful, crippling bleeding in patients joints. Patients currently require life-long treatment with concentrates of clotting factor administered intravenously on an on-demand or prophylactic basis.
Freeline’s world-class technology could replace the need for chronic enzyme treatment in genetic diseases such as haemophilia B with a single injection, providing the possibility of long-term disease modification.
- Chris Hollowood
- Dominic Schmidt
- Prof. Amit Nathwani